NuCana plc (NCNA)
Develops cancer drugs that make chemotherapy medicines work better inside tumor cells.
$1.29+0.02%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-83.5%
The outlook
NCNA is trading near its 52-week low with minimal upward momentum, sitting below both its 50- and 200-day moving averages. Analyst sentiment is bearish overall, and the stock shows very limited trading activity near the bottom of its recent range.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range1% of the way from its 52-week low to high
Market cap
$5.4M
52-wk high
$10.60
52-wk low
$1.21
50-day avg
$1.72
200-day avg
$2.67
Trailing P/E
0.0